Retinoblastoma (RB) is one of the most common childhood cancers caused by RB gene mutations (tumor suppressor gene in various patients). A better understanding of molecular pathways and the development of new diagnostic approaches may lead to better treatment for RB patients. The number of studies on ceRNA axes is increasing, emphasizing the significance of these axes in RB. Circular RNAs (circRNAs) play a vital role in competing endogenous RNA (ceRNA) regulatory axes by sponging microRNAs and regulating gene expression. Because of the broadness of ceRNA interaction networks, they may assist in investigating treatment targets in RB. This study conducted a systematic scoping review to evaluate verified loops of ceRNA in RB, focusing on the ceRNA axis and its relationship to circRNAs. This scoping review was carried out using a six-step strategy and the Prisma guideline, and it involved systematically searching the publications of seven databases. Out of 363 records, sixteen articles were entirely consistent with the defined inclusion criteria and were summarized in the relevant table. The majority of the studies focused on the circRNAs circ_0000527, circ_0000034, and circTET1, with approximately two-fifths of the studies focusing on a single circRNA. Understanding the many features of this regulatory structure may help elucidate RB’s unknown causative factors and provide novel molecular potential therapeutic targets and medical fields.

Keywords: retinoblastoma, circular RNA, CeRNA, sponge, circ_0000527, circ_0000034, circTET1

Abbreviations: RB, Retinoblastoma; ceRNA, Competing endogenous RNA; CircRNA, Circular RNA; MRE, MicroRNA Response Element; PRISMA-ScR, Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews; RBP, RNA-binding protein; dsRNA, double-stranded RNA; snRNP, small nuclear ribonucleoprotein; ORF, open reading frame; GFP, green fluorescent protein; CRC, Colorectal Cancer; TSGs, tumor suppressor genes; TNBC, triple negative breast cancer.
1 INTRODUCTION

Retinoblastoma (RB) is the most frequent type of childhood eye tumor. RB is caused by a mutation in the tumor suppressor gene Rb1. It is well-known that RB is a typical illustration of Knudson’s two-hit theory (1). It is a rapidly developing tumor, with a doubling period of 15 days in highly young patients (2). The global prevalence of RB ranges between 1/15,000 and 1/20,000 live births (3). The International Classification of RB categorizes intraocular tumors based on tumorigenesis and pattern. They are divided into five categories: A through E. The odds of saving the eye diminish as the group progresses from A to E. Enucleation is favored in unilateral patients (tumor in a single eye) when the malignancy reaches Groups D and E. In bilateral patients (tumors in both eyes), the eye with the most advanced tumor is enucleated (4). External beam radiation, episcleral plaque radiotherapy, enucleation, cryotherapy, and photocoagulation were formerly the standard therapies for children with RB (5). RB therapy has evolved significantly during the last decade. In this regard, with shifting views on radiotherapy concerns, intravenous and intra-arterial chemotherapies have become the cornerstone of RB treatment since they have been proven to efficiently reduce tumor size, metastasis, and preserve eyesight (6). However, their clinical applicability is restricted owing to the possibility of systemic toxicity, drug resistance, and fast blood clearance (7).

Remarkably, attention to the molecular mechanisms like toxicology, drug resistance, and fast blood clearance (7). The latter are short RNAs of 21–23 nucleotides in length that may lead Argonaute proteins to target transcripts by base pairing, causing them to degrade or repress translation (9, 10). Franco-Zorrilla et al. described a phenomenon known as ‘target mimicry’ in which a non-coding RNA in plants may sequester miR-399 and repress its target (11). Not long after, Ebert et al. discovered a similar phenomenon in animal cells. Ectopic production of a miRNA that has a large number of binding sites (also referred to as miRNA response elements (MREs)) results in miRNA sequestration that is hardly visible but leads to a 1.5- to 2.5-fold overexpression of the targets of the miRNA in this research (12). As a result, the term "RNA sponge" was created to characterize the phenomenon of miRNAs being absorbed by overexpressed MRE-containing transcripts. Following that, the RNA sponge phenomenon was found in various malignancies (13, 14). The term ‘ceRNA’ was created in 2011 to characterize this additional layer of posttranscriptional control (15).

Circular RNA (circRNA) is a non-coding RNA that primarily regulates biological processes via gene control. CircRNAs contain many binding sites for miRNA and hence operate like sponge, absorbing miRNAs (16). CircRNA may also interact with other RNAs through base pairing (17). Furthermore, by interacting with proteins, circRNA may limit their function (18).

Although circRNA is a form of non-coding RNA, under specific circumstances, it may serve as a translation template for protein synthesis and yield functional proteins (19). CircRNAs have recently been discovered to affect host gene expression, interact with RNA-binding proteins that govern transcription, function in cis transcriptional regulation, and even regulate and control alternative splicing (20). The fact that ceRNA interaction networks are multifactorial means that they may be valuable in investigating complicated diseases such as RB in terms of therapeutic targets since by targeting just one of them, the levels of several disease-related RNAs change simultaneously (21). We performed a systematic scoping review in this study to look into validated ceRNA loops in RB. The focus of our study was the circRNA-ceRNA axes, which have been associated with RB etiology and might be utilized as therapeutic targets.

2 METHODS

The approach for this study was based on Arksey and O’Malley’s (22) scoping review framework, which was subsequently revised by Levac et al. (23). This process consists of five unique steps: (1) identifying the research question, (2) identifying relevant studies, (3) study selection, (4) data charting, and (5) collating, summarizing, and reporting results. We did not use consultation in our research, an optional sixth stage in the scoping review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) Checklist also effectively guided this review (24).

2.1 Identifying the Research Question

The purpose of this study was to compile and organize the existing information on circRNA-associated ceRNA loops in RB. In order to achieve this goal, we aimed to respond to the following question: What is known about circRNA-associated ceRNA regulatory axes in RB based on the extant literature?

2.2 Identifying Relevant Studies

An initial restricted search of PubMed and Embase was carried out, and then the keywords in the title and abstract, as well as the index terms that were used in the articles, were evaluated for significance. A second search was conducted throughout the PubMed, Embase, Scopus, Web of Science, and Cochrane databases without any restrictions, using keywords, MeSH, or Emtree terms identified in the original search. Additionally, searches were conducted in two gray-listed (i.e., difficult to find or unpublished) literature databases: Google Scholar and ProQuest. The most recent search was conducted on March 23, 2022. We also looked through the reference lists of relevant literature and reviewed papers for additional sources.

2.3 Study Selection

The included papers met the following criteria: (1) explicitly discussing the circRNA-associated ceRNA axis in RB, (2) published in English, and (3) be original research. The exclusion criteria were: (1) non-RB or any ocular tumor studies, (2) studies that did not utilize human specimens or
cell lines, and (3) studies that did not use a molecular approach to verify the ceRNA loop components. The title and abstract of each article were separately reviewed for eligibility according to the criteria mentioned earlier by two reviewers (MRA, HS). The remaining publications’ entire texts were assessed, and those that met the eligibility requirements were included in the final data analysis. Any differences were resolved via conversation or, if necessary, with a third reviewer (MR).

2.4 Data Charting
Two reviewers (MRA and HS) extracted data separately into a predesigned charting template in Microsoft Excel. It listed the first author, the year of publication, the country, the type of study, the cell line(s), human samples, animal models, methods, ceRNAs, shared miRNAs (s), and the key findings.

2.5 Collating, Summarizing, and Reporting the Results
We conducted both quantitative and qualitative analyses. We produced a descriptive numerical overview of the features of the included articles for the quantitative section. As part of the qualitative analysis, we wrote a narrative review of the current information that answered our research question, focusing on how important the results were in a larger context, as suggested by Levac et al. (23).

3 RESULTS
3.1 Search Results
The flow chart in Figure 1 depicts the various steps involved in locating eligible studies. A total of 363 articles were identified from multiple sources, of which 176 were duplicates. One hundred seventy-one articles were omitted due to their insignificance. After reading the full texts of the remaining 16 articles for the purpose of evaluation, the results are presented in Table 1.

3.2 Study Characteristics
Eligible studies were published between 2019 and 2022. These studies included 465 samples of RB patients and 343 healthy controls, based on the mentioned number. One hundred seventy-one articles were omitted due to their insignificance. After reading the full texts of the remaining 16 articles for the purpose of evaluation, the results are presented in Table 1.

4 DISCUSSION
4.1 CircRNA Features and Biogenesis
A recent study has shown that circRNAs are commonly formed from one to five exons, with lengths ranging from just a few hundred to thousands of nucleotides (41). CircRNAs produced via back-splicing have numerous fundamental properties: I. Circular RNAs have a closed ring shape, which means they lack either 5’-3’ polarity or a polyadenylated tail, making them resistant to exonuclease degradation and much more stable than linear RNA (42). II. CircRNAs are frequently expressed in eukaryotic cells, and high-throughput sequencing has shown that more than one million circRNAs exist in human tissues (43). III. The majority of circRNAs are found in the cytoplasm, with a minor number of circRNAs found in the nucleus as well (44). IV. The majority of circRNAs contain substantially conserved sequences across various species (45). V. CircRNAs demonstrate tissue-and developmental-stage-specific and dynamic expression patterns (46). VI. CircRNAs act as transcriptional or posttranscriptional regulators (44).

It is critical to understand how circRNAs are created in order to classify them. In conjunction with the activation of the spliceosomal machinery, canonical splicing is a process in which the introns of precursor messenger RNAs (pre-mRNAs) are removed, and exons are then joined to generate mature messenger RNAs (47). In contrast to canonical splicing of miRNAs, circular RNAs are produced by nonsequential back-splicing of pre-mRNAs by spliceosomes rather than conventional splicing (5). Back-splicing is the process of reversibly joining the upstream 5’ splice donor site to the downstream 3’ splice acceptor site to form a covalently closed structure (5, 48). According to recent research, back-splicing requires both conventional splicing signals and canonical splicing machinery (49, 50).

Two key factors may aid back-splicing circularization: intron pairing and RNA-binding proteins (RBPs). On one hand, intron pairing causes exons to approach one another through ALU elements (51) or nonrepetitive yet complementary sequences.
### TABLE 1 | Circular RNAs in Retinoblastoma ceRNA axes.

| First author | Year of publication | Country | Type of study | Human samples | Cell line(s) | Animal model | Methods | CeRNAs | SharedmiRNA | Key findings | ref |
|--------------|-------------------|---------|---------------|---------------|-------------|-------------|---------|--------|-------------|--------------|-----|
| Du et al.    | 2019              | China   | Human study, Cell culture, Animal study | 60 RB tissues and 60 normal retina tissues | Y79 HXO-RB44 SO-Rb50 WERI-Rb-1 ARPE-19 | athymic mice | Cell transfection, q-PCR, Western blot, Cell proliferation assays, Nuclear/cytoplasmic fractionation, Dual-lucerase reporter assay | circ_ODC1 and SKP2 | miR-422a | It was discovered that SKP2 was disinhibited by circ_ODC1 from miR422a, which resulted in increased RB proliferation. | (25) |
| Chen et al.  | 2020              | China   | Human study, Cell culture | 30 human RB samples and 30 adjacent normal tissues | Y79 HXO-RB44 SO-Rb50 WERI-Rb-1 ARPE-19 | – | q-PCR, CCK-8 assay, TUNEL, Transwell assay, Dual-lucerase reporter gene assay, RIP assay, Western blot | circ_0000527 and BCL-2 | miR-646 | Circ_0000527 expression was considerably higher in RB samples compared to normal tissues, whereas miR-646 expression was significantly lower. Circ_0000527 increased the viability, migration, and invasion of RB cells and sponged miR-646 to regulate BCL-2 expression. | (26) |
| Liu et al.   | 2020              | China   | Human study, Cell culture, Animal study | 32 RB tissues and 6 normal retina tissues | Y79 HXO-RB44 SO-Rb50 WERI-Rb-1 ARPE-19 | SCID mice | q-PCR, RNase R Treatment, Cell Transfection, Cell Proliferation Assay, Cell Apoptosis Assay, Cell Migration and Invasion Assay, Western Blot, Dual-Lucerase Reporter Assay, RIP Assay | circ_0000034 and STX17 | miR-361-3p | Circ_0000034 increased STX17 levels by sponging miR-361-3p. Circ_0000034 knockdown suppressed RB cell growth by influencing the miR-361-3p/STX17 axis. | (27) |
| Sun et al.   | 2020              | China   | Human study, Cell culture | 38 RB tissues and 12 normal retina tissues | Y79 SO-Rb50 WERI-Rb-1 ARPE-19 | – | q-PCR, Subcellular fractionation location, EdU assay, Wound healing assay, Transwell invasion assay, RIP assay, Luciferase reporter assay | circ_0000034 and miR-361-3p targets | miR-361-3p | Circ_0000034 was overexpressed in RB, and increased expression levels of Circ_0000034 are related to a malignant phenotype. Circ_0000034 appeared to function as a ceRNA in RB via miR-361-3p sponging. | (28) |
| Wang et al.  | 2020              | China   | Human study, Cell culture, Animal study | 15 RB tissues and 10 normal retina tissues | Y79 WERI-Rb-1 | BALB/c nude mice | q-PCR, Transfection Assay, Colony Formation Assay, Flow Cytometry Analysis, Transwell Assay, Western Blot, Dual Luciferase Reporter Assay | CircDHDDS and WNT3A | miR–361–3p | CircDHDDS by sponging miR-361-3p regulate WNT3A expression. As a result, the circDHDDS/miR-361-3p/WNT3A axis promoted RB development by regulating RB cell growth, cell cycle program, migration, and invasion. | (29) |
| Zhang et al. | 2020              | China   | Human study, Cell culture | 45 human RB samples and 45 adjacent normal samples | Y79 SO-Rb50 RB355 WERI-Rb-1 ARPE-19 | – | q-PCR, CCK–8 assay, Flow cytometry, Transwell migration and invasion assays, Western blot, RIP assay, Dual-lucerase reporter assay | Circ_0000527 and LRP6 | miR-646 | Circ_0000527 overexpression promoted RB cell growth, migration, and invasion while suppressing cell apoptosis, whereas circ_0000527 knockdown suppressed malignant biological behavior. Circ_0000527 regulated LRP6 expression by directly targeting miR-646. | (30) |

(Continued)
| First author | Year of publication | Country | Type of study | Human samples | Cell line(s) | Animal model | Methods | CeRNAs | SharedmiRNA | Key findings | ref |
|--------------|---------------------|---------|---------------|---------------|-------------|--------------|---------|--------|-------------|--------------|-----|
| Fu et al.    | China 2021          | Human study, Cell culture, Animal study | 30 RB tissues and 30 normal retina tissues | Y79 WERI-Rb-1 ARPE-19 | BALB/c nude mice | q-PCR, Nuclear and cytoplasmic fraction assay, Cell viability assay, Colony formation assay, Flow cytometry, Scratch assay, Transwell assay, Western blot, Dual-luciferase reporter assay, RNA pull-down assay | CircTET1 and miR-492 and miR-494-3p targets | miR-492 | miR-494-3p | CircTET1 expression was decreased in RB tissues and cells, whereas its overexpression inhibited RB cell progression. CircTET1 acted as a sponge for miR-492/miR-494-3p, which inhibited the Wnt/-catenin pathway. | (31) |
| Huang et al. | China 2021          | Human study, Cell culture, Animal study | 23 RB tissues and 16 normal retina tissues | Y79 SO-Rb50 WERI-Rb-1 ARPE-19 SO-Rb70 | BALB/c nude mice | q-PCR, RNase R assay, Cell proliferation, Flow cytometry, Transwell assay, Wound healing assay, Dual-luciferase reporter assay, Western blot, IHC | Circ-E2F3 and ROCK1 | miR-204-5p | | Circ-E2F3 as a tumor promoter promoted RB proliferation, metastasis, and apoptosis by modulating the miR-204-5p/ROCK1 axis. | (32) |
| Jiang et al. | China 2021          | Cell culture, Animal study | – | Y79 SO-Rb50 WERI-Rb-1 ARPE-19 SO-Rb70 | BALB/c nude mice | q-PCR, Nuclear and cytoplasmic fraction assay, Colony formation assay, Flow cytometry, Transwell analysis, Caspase-3/8 caspase-9 activity assay, Dual-luciferase reporter assay, RIP assay, RNA pull-down assay, Western blot | Circ_0099198 and LRP6 | miR-1287 | | Circ_0099198 depletion suppressed RB cell progression by regulating the miR-1287/LRP6 axis. Circ_0099198 aided RB progression through sponging miR-1287 and increasing LRP6 expression. | (33) |
| Xu et al.    | China 2021          | Human study, Cell culture, Animal study | 55 human RB samples and 55 adjacent normal samples | Y79 WERI-Rb-1 ARPE-19 | BALB/c nude mice | q-PCR, Subcellular fraction assay, Cell transfection, CCK-8 assay, Colony formation assay, Transwell assay, Western blot, Dual-luciferase reporter assay, RIP assay | CircMKLN1 and PDCD4 | miR-425-5p | | CircMKLN1 expression was reduced in RB tissues and cells. Elevated levels of circMKLN1 were linked to a better outcome in RB patients. In addition, circMKLN1 is a target gene for miR-425-5p. Silencing PDCD4 may improve the inhibitory roles of circMKLN1 in RB cell development and metastasis. | (34) |
| Jiang et al. | China 2021          | Human study, Cell culture, Animal study | 30 human RB samples and 30 adjacent normal samples | Y79 SO-Rb50 WERI-Rb-1 ARPE-19 | BALB/c nude mice | q-PCR, CCK-8 assay, Transwell assay, Flow cytometry assay, Caspase-3 activity assay, Western blot, Dual-luciferase reporter assay, RIP assay, RNA pull-down assay | Circ_0000334 and ADAM19 | miR-361–3p | | Circ_0000334 Silencing suppressed RB progression by down-regulating ADAM19 through miR-361-3p sponging. | (35) |
| Zhang et al. | China 2021          | Human study, Cell culture, Animal study | 47 RB tissues and 9 normal retina tissues | Y79 WERI-Rb-1 HXO-Rb44 | BALB/c nude mice | RNase R or actinomycin D treatment, q-PCR, Cell transfection, CCK8 assay, EdU assay, Flow | Circ_0075804 and PEG10 | miR-138-5p | | Circ_0075804 assisted the malignant characteristics of RB cells by binding to miR-138-5p and causing PEG10 expression. | (36) |

(Continued)
| First author | Year of publication | Country | Type of study | Human samples | Cell line(s) | Animal model | Methods | CeRNAs | SharedmiRNA (s) | Key findings ref |
|--------------|---------------------|---------|---------------|---------------|-------------|-------------|---------|--------|----------------|----------------|
| Liang et al. | 2021 China          | Cell culture, Animal study | ARPE-19 | q-PCR, Western blot assay, Dual-luciferase reporter assay, RIP assay | Circ_0000527 and SMAD2 | miR-1236-3p and SMAD2 | (37) |
| Yu et al.    | 2021 China          | Human study, Cell culture, Animal study | 27 RB and 19 normal retina tissues | q-PCR, Cell proliferation assay, Colony formation assay, Flow cytometry, Transwell assay, Scratch assay, Dual-luciferase reporter assay, RIP assay, Western blot assay | Circ_0000527 and XIAP | miR-98-5p and XIAP | (38) |
| Zheng et al. | 2021 China          | Human study, Cell culture, Animal study | 33 RB and 21 normal retina tissues | q-PCR, RNase R treatment, Flow cytometry, Transwell assay, Dual-luciferase reporter assay, Western blot, IHC, TUNEL assay | Circ-FAM158A and SLC7A5 | miR-138-5p and SLC7A5 | (39) |
| Zuo et al.   | 2022 China          | Human study, Cell culture, Animal study | NR | q-PCR, CKK-8 assay, colony formation assay, Flow cytometry, Dual-luciferase reporter assay, RIP assay, Western blot | Circ_0000527 and HDAC9 | miR-27a-3p and HDAC9 | (40) |
Long flanking introns with complementary ALU repeats are essential for developing circHIPK3 (53). On the other hand, some RBPs, such as MBL (MBNL1), QKI, and FUS (54), have the ability to bind firmly and precisely to conserved regions of flanking introns, thus promoting exon circularization and, ultimately, the production of circular RNAs. Furthermore, the action of adenosine deaminase (ADAR) specific to double-stranded RNA (dsRNA) on the editing of adenosine to inosine (50) and the unwinding of the dsRNA helix structure by ATP-dependent RNA helicase A (also known as DHX9) suppresses the synthesis of circRNAs (55, 56). Furthermore, circRNA production may be aided by SFs such as ESRP1 (57) and the elongation velocity of RNA polymerase II (58).

4.2 CircRNAs’ Functional Mechanisms

4.2.1 MiRNA Sponge

CircRNAs are involved in a wide range of biological activities because of their distinct structures and other characteristics (59). The capacity of circRNAs to act as miRNA sponges is their most notable function. CircRNAs that include miRNA binding sites bind directly to the matching miRNAs, inhibiting miRNA function and regulating target gene expression. The first circRNA to act as a ceRNA was CDR1as (antisense to the cerebellar degeneration-related protein 1 transcript), which has more than 60 conserved binding sites for miR-7 (44, 60). It bonded to miR-7 and inhibited midbrain growth in zebrafish, comparable to miR-7 knockdown. Hansen et al. hypothesized the same year that mouse circRNA circMbl, produced from the second exon of the splicing factor muscle blind (MBL/MBNL1), might compete with linear splicing pre-mRNA (50). MBL levels considerably influence circMbl biosynthesis depending on the MBL binding sites. CircMbl has the potential to inhibit the synthesis of its parental mRNA. Another noteworthy example was published in 2015, demonstrating that circRNAs might govern the transcription of the genes they regulate (68). Li et al. discovered that a subclass of circRNA called ElciRNA was mainly located in the nucleus and stimulated transcription of their parental genes by interacting with U1 snRNP, revealing a unique regulatory mechanism for transcriptional control via specialized RNA-RNA interactions (68).

4.2.2 Splicing or Transcriptional Regulation

Alternative splicing is frequently related to a variety of biological activities (66). CircRNAs were discovered to influence alternative splicing through RNA-mediated interaction, therefore influencing gene expression (67). According to Ashwal-Fluss et al., circMbl, produced from the second exon of the splicing factor muscle blind (MBL/MBNL1), might compete with linear splicing pre-mRNA (50). MBL levels considerably influence circMbl biosynthesis depending on the MBL binding sites. CircMbl has the potential to inhibit the synthesis of its parental mRNA. Another noteworthy example was published in 2015, demonstrating that circRNAs might govern the transcription of the genes they regulate (68). Li et al. discovered that a subclass of circRNA called ElciRNA was mainly located in the nucleus and stimulated transcription of their parental genes by interacting with U1 snRNP, revealing a unique regulatory mechanism for transcriptional control via specialized RNA-RNA interactions (68).
and the anti-stress proteins FAK and HIF1α and holds them in the cytoplasm, preventing them from performing their respective duties (72).

### 4.2.4 Translate Proteins

Although circRNAs are classified as non-coding RNAs, growing evidence suggests that certain circRNAs are translatable (47). Unlike mature mRNA translation, which generally requires the presence of a 5′ end 7-methylguanosine (m7G) cap structure and a 3′ poly(A) tail, circRNA translation is distinct because it does not need the presence of these structures (73). It was proven in 1998 that a circular mRNA containing the whole open reading frame (ORF) of green fluorescent protein (GFP) could effectively encode GFP in Escherichia coli (74). Legnini et al. discovered that circ-ZNF609 includes an ORF and may be translated into a protein in murine myoblasts when activated by IRES (75). Further research found that certain circRNAs containing internal ribosome entry sites (IRESs) may function as the entrance point for ribosomes, therefore triggering translation (76, 77). Surprisingly, the most prevalent RNA modification, N6-methyladenosine (m6A), was discovered to improve circRNA protein-coding capacity (78). According to recent research, FBXW7-185aa, a new 21-kDa protein, was encoded via a spanning junction open reading frame in circ-FBXW7 that was directed by an internal ribosome entry site. In glioblastoma, upregulation of FBXW7-185aa suppressed proliferation and cell cycle progression, as well as reduced the half-life of c-Myc by antagonizing USP28-induced c-Myc stabilization, while knockdown of FBXW7-185aa increased malignant phenotypes both in vitro and in vivo, as previously reported (79). Similarly, Pamudurti N. R. et al. discovered that circMbl could also translate proteins without the need for a cap (80). The protein-coding function shed new light on the involvement of circRNAs in diseases.

### 4.3 CircRNA: Oncogene or Tumor Suppressor Gene

Emerging evidence suggests that dysregulated circRNAs have both tumor-suppressive and oncogenic roles in cancer origin and development, affecting a wide range of cellular processes. The tumor structure is comprised of cells that have mutations in the genes involved in proliferation and differentiation (81). Oncogenes contribute to the stimulation of cell proliferation. Changes in these genes may vary from the development of novel oncoproteins to the overexpression of previously proto-oncogenes. In contrast, tumor suppressor genes (TSGs) inhibit cell growth through the opposite mechanism (82). In this regard, the role of several circRNAs as oncogenes has been investigated. Circ-ABCB10 has been identified as a breast cancer oncogene, and circ-ABCB10 knockdown suppresses proliferation and increases apoptosis in breast cancer cells (83). Similarly, circ-ZEB1 was one of the oncogenic circRNAs that was significantly higher in triple-negative breast cancer (TNBC) tumor tissues and tumor cell lines (84). Circ-ZEB1 knockdown has been shown to reduce TNBC cell proliferation and tumor formation by releasing miR-448 and consequently decreasing the expression of the miR-448 target, eEF2K (84). CircCD44 with oncogenic roles is substantially expressed in TNBC and is adversely correlated with TNBC patient prognosis (85). CircCD44 enhances TNBC proliferation, migration, invasion, and tumorigenesis (85). Remarkably, the oncogenic role of circRNAs in other cancers has also been considered, including circRNA_100859 (86), circAGO2 (87), PIP5K1A (88), circPPP1R12A (89), CCDC66 (90), GLIS2 (91), and circ_0084615 (92) in colon cancer, circRNA-C190 (93), circNDUFB2 (94), circ_100146 (95), circRNA_001846 (96), and circ_0087862 (97) in lung cancer, circAF4 (98), and circSPI1 (99) in leukemia.

On the contrary, studies have shown changes in circRNAs and their functions as TSGs. Circ_0006220 expression was lower in TNBC compared to other subtypes of BC tissues and cell lines. Notably, circ_0006220 functions as a TSG, inhibiting TNBC cell proliferation, migration, and invasion (100). CircCDYL was down-regulated in TNBC tissues, and its expression was found to be positively associated with patient survival rates (101). CircCDYL induces apoptosis and suppresses the proliferation of breast cancer cells with a malignant phenotype (101). The function of circRNAs as TSGs has also been proven in many cancers, including circDDX17 (102), circ_PLXNB1 (103), circTADA2A (104), and Circ-SMARCA5 (105) in colorectal cancer, circ_0004872 (106), circDIDO1 (107), circMAPK1 (108), circ_0035445 (109) and circCCD9 (110) in gastric cancer, circPLEKHM3 (111) in ovarian cancer, circ-MYBL2 (112) in multiple melanoma, and circSLC8A1 (113) in prostate cancer.

### 4.4 Potentials of CircRNAs in CeRNA Axes

Several circRNAs exhibit tissue and developmental stage-specific expression patterns (44). According to recent research, the global abundance of circRNAs was decreased in colorectal cancer (CRC) tissues compared to normal tissues (114). The abundance of a circRNA known as Has-circ-002059 was likewise lower in malignant vs. non-cancerous tissues in gastric cancer (115). Another recent study detected circRNAs in exosomes (small membrane vesicles with endocytic origins released by cells) and discovered that the profiles of serial exosomal circRNAs may identify CRC patients from healthy controls (116). Figure 3 illustrates a schematic view of the overall function of circRNAs.

The structure of circular RNAs is relatively similar to that of linear RNAs, but they are typically more stable than their linear counterparts because they lack accessible ends and are hence resistant to exonucleases (44). It has been hypothesized that circRNA may create active ceRNA pairs with their linear counterparts due to their unique characteristics like miRNA sponging. CDR1as, a brain-enriched circRNA, has been reported to act as a miRNA sponge for miR-7 in a variety of human disorders (44, 61), including colon cancer (117), gastric cancer (118), esophageal cancer (119), and myocardial infarction (120). Other ceRNA connections discovered in cancer include circPT1-miR125 in gastric cancer (64), circITCH-miR7/miR214 in lung cancer (121), circHIPK3-miR124 in liver cancer (122), and circTTBK2-miR217 in glioma (123).
In addition, it is interesting that the ceRNA axes in RB have received much attention as a representative of ocular tumors in recent years, and the potential of these regulatory axes is becoming more and more meaningful. On the other hand, studies on axes involving circRNAs in RB are still in their infancy and can play an essential role in the cell by considering the properties of a circRNA. In the following, studies on ceRNA axes in which circRNAs play a crucial role have been obtained in the form of a systematic review study and will be further discussed, and it is expected that this study can be a guide for further studies in this field and cause these studies to receive more attention (Figure 4).

4.5 Circ_0000527
CircRNA's function in carcinogenesis and cancer development has received much interest. CircRNA contributes to tumor development by controlling cancer cells' malignant biological activities such as proliferation, apoptosis, and metastasis (124). Circ_0001649 is claimed to inhibit RB cell proliferation and apoptosis by blocking the AKT/mTOR signaling pathway, and its low expression level implies a bad prognosis in patients (125); circ_ODC1 positively regulates SKP2 and increases RB cell proliferation (25). Surprisingly, it was revealed in another study that the expression level of circ_0000527 in RB tissues and cells was dramatically elevated and that its high expression was closely connected with the degree of differentiation and cTNM staging (30). These findings suggest that circ_0000527 was likely to predict a poor prognosis in RB patients (30). Furthermore, circ_0000527 overexpression significantly increased cell proliferation, motility, and invasion while significantly decreasing cell apoptosis (26). On the other hand, knocking down circ_0000527 had the opposite effect (30, 38). At the same time, miR-646 expression in RB showed a significant decrease, and since miR-646 has several binding sites for circ_0000527, further studies confirmed that circ_0000527 negatively regulates miR-646 expression (26). Interestingly, LRP6, which is regulated by miR-646 and is one of the primary expression genes expressed in malignancies, also experienced a significant increase in expression in the form of a ceRNA axis due to the sponging of miR-646 by circ_0000527 (30). However, studies on increasing the expression of LRP6 in the form of the ceRNA axis in RB were not stopped, and sponge miR-1287 confirmed the increase in the expression of this gene by circ_0099198 in another study (33). Circ_0099198 in RB experiences a significant increase in expression, and this increase
in expression shows its effects by decreasing the expression of miR-1287, which is responsible for regulating the expression of LRP6 (33).

Most notably, miR-646 has been identified as a tumor suppressor in a variety of human malignancies. For example, miR-646 inhibits cell growth and migration in lung cancer by negatively regulating the EGFR/Akt pathway (126); in colorectal cancer, miR-646 inhibits cancer development by suppressing NOB1 (127). MiR-646 inhibits the spread of clear cell renal carcinoma cells by downregulating the nin one binding protein (128). MiR-646 suppresses non-small cell lung cancer growth and metastasis through binding to FGF2 and CCND2 (129). In this regard, miR-646 transfection in RB cells was associated with decreased viability, migration, and invasion of these cells (26). Although the oncogenic effects of circ_0000527 have been demonstrated by sponge miR-646, another ceRNA axis was identified by miR-646 targeting BCL-2. Increased circ_0000527 expression by miR-646 sponging increased BCL-2 expression (26), which is one of the significant genes in various malignancies (130).

Circ_0000527 acted as a sponge for miR-1236-3p, which targeted SMAD2 directly, and as a result, miR-1236-3p expression was reduced in RB tissues and cells (37). Circ_00000527 knockdown on RB cell malignancy reduced the effects of MiR-1236-3p inhibition. Furthermore, miR-1236-3p overexpression inhibited RB cell development, whereas SMAD2 elevation reversed the impact (37). Moreover, circ_0000527 knockdown inhibited tumor development in vitro (38). Circ_0000527 also sponges miR-98-5p to form another ceRNA axis, promoting the development of RB by increasing the expression of the miR-98-5p target gene, which is XIAP (38).

Nonetheless, investigations in RB on circ_0000527 have demonstrated an increase of this circRNA in the presence of the ceRNA axis, which enhances the expression of genes that lead to the formation and progression of RB and even respond to role the ceRNA axis, which enhances the expression of genes that lead to the formation and progression of RB and even respond to role.

**4.7 Other CircRNAs**

The ceRNA axes inside the cell are in equilibrium under normal conditions. Increasing or decreasing the expression of each component of an axis can advance the trend in favor of abnormal conditions. The majority of circRNAs studied in the form of ceRNA axes are associated with increased expression, but circTET1 in RB is disturbed by decreased expression of the desired ceRNA axis. It was discovered that CircTET1 expression was downregulated in RB tissues and cells and that its upregulation hampered the growth of RB cells in culture. CircTET1 was shown to be a miR-492/miR-494-3p sponge, and it blocked the Wnt/catenin pathway via miR-492/miR-494-3p (31). Similarly, circMKLN1 expression was reduced in RB tissues and cells. Elevated levels of circMKLN1 were linked to better results in RB patients. CircMKLN1 overexpression inhibited RB cell proliferation, migration, and invasion in vitro. MiR-425-5p was shown to be a target of circMKLN1, and it was discovered that increasing miR-425-5p levels might counteract the effects of circMKLN1 overexpression on RB cell malignant tendencies. Furthermore, because circMKLN1 is a target gene for miR-425-5p, suppressing PDCD4 may enhance circMKLN1’s inhibitory effects in RB cell development and metastasis (34).

Nonetheless, the rest of the circRNAs, which have only been studied in one study, have been shown to experience increased expression. Among these, miR-138-5p is considered one of the potential miRs in RB, which is located in specific ceRNA axes due to binding sites for circ_0075804 and circ-FAM158A (36, 39). The circ_0075804/miR-138-5p/PEG10 axis was identified as a ceRNA axis in RB. Through its interaction with miR-138-5p, Circ_0075804 led to the development of the malignant phenotypes of RB cells. Circ_0075804 By sponging, miR-138-5p acts as a barrier to the activity of this miR and cannot regulate the expression of its target gene, which is PEG10, and as a result, PEG10 expression is significantly increased, which acts to cause oncogenic effects in RB (36). Similarly, circ-FAM158A and SLC7A5 were up-regulated, and miR-138-5p was down-regulated in RB. Circ-FAM158A silencing inhibited RB cell proliferation, invasion, and migration while promoting G0/G1 cell cycle arrest and cell apoptosis. Circ-FAM158A functioned as an oncogene in RB by sponging miR-138-5p, which regulates sLC7A5 expression (39).

On the other hand, Circ-E2F3 was shown to be increased in RB tissues and cells, and silencing of circ-E2F3 suppressed RB cell proliferation, migration, invasion, and triggered apoptosis in vitro, as well as reduced RB tumor development in vivo. Circ-E2F3 sponged MiR-204-5p, and its inhibitor restored the inhibitory impact of circ-E2F3 silencing on RB progression. Furthermore, ROCK1 is known as the target for miR-204-5p,
and it is able to control RB development by regulating ROCK1. Moreover, through sponging miR-204-5p, circ-E2F3 favorably regulated ROCK1 expression (32). Finally, given that studies of ceRNA axes centered on circRNAs are at the beginning of the path, and given what genes with potential are involved in these regulatory axes, it will demonstrate the increasing importance of these regulatory axes in RB. The importance of these genes involved in ceRNA axes will be discussed in the following.

4.8 Genes Involved in CircRNA-Associated CeRNA Axes

It is desirable to further discuss the genes located in the ceRNA axes in these studies, which are among the genes that have the potential for various cancerous processes. The genes in these ceRNA axes include SMAD2, ROCK1, WNT3A, STX17, LRP6, HDAC9, BCL-2, SLC7A5, ADAM19, XIAP, PEG10, PDCD4, and SKP2. The majority of these genes experience increased expression due to up-regulation of their ceRNA axis circRNA, but PDCD4 experiences reduced expression due to decreased circmKLN1 expression and a reduced ability to sponge miR-425-3p (34). PDCD4 is a new tumor suppressor that exhibits a wide range of actions, including the inhibition of cell proliferation, tumor invasion, metastasis, and the induction of apoptosis. In addition to binding to the translation initiation factor eIF4A and several transcription factors, the PDCD4 protein interacts with a variety of other factors, modulating their functions (131). Decreased expression of this tumor suppressor gene in RB acts in favor of the progression of this malignancy and leaves its effects. Among these, Wnt3A, a member of the Wnt family, is a transcription factor that regulates various cellular processes, including self-renewal, proliferation, differentiation, and motility. Increasing evidence suggests that Wnt3A, depending on the cancer type, either stimulates or inhibits tumor growth via the canonical Wnt signaling pathway (132). In RB development, it acts by increasing the expression induced by the circDHDDS/miR-361-3p/WNT3A ceRNA axis with one of the targets of Wnt3A. ROCK1 is involved in cell motility, angiogenesis, and migration (149). Furthermore, ROCK1 has been found to be overexpressed in a variety of solid tumors, including glioblastoma (150), melanoma (151), osteosarcoma (152), and hepatocellular carcinoma (153). According to published reports, ROCK1 overexpression is strongly associated with more highly metastatic and invasive phenotypes in human cancers (149). In this regard, ROCK1 is overexpressed in RB as part of a ceRNA axis, which promotes RB proliferation, metastasis, and invasion while decreasing apoptosis (32). Similarly, according to several research findings, HDAC9 has been implicated in the development of malignant tumors. HDAC9 overexpression has been linked to cell growth in medulloblastoma (154), lymphoma (155), oral squamous cell carcinoma (156), and breast cancer (157). It should be noted that the overexpression of this gene in RB was also proven in a study, but this increase in expression was not detected in the form of a ceRNA axis (158). HDAC9 experiences increased expression in the form of the circ_0000527/miR-27a-3p/HDAC9 ceRNA axis and exerts its oncogenic properties by activating the PI3K/AKT pathway (40). STX17 (Syntaxin 17) is an autophagy-related ER-resident SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein. Various roles for STX17 in terms of its mechanisms of action have been proposed (159).

XIAP overexpression in tumor cells has been linked to tumor aggressiveness and has been described as a mediator of resistance to chemotherapy and targeted therapy in various malignancies (160). In RB, the increase in XIAP expression also occurs due to the sponging of miR-98-5p by circ_0000527, which acts in the direction of the oncogenic properties of XIAP (38). Likewise, PEG10 appears to play a critical role in tumor growth in a variety of cancers, including hepatocellular carcinoma (161), lung cancer (162), and prostate cancer (163). In RB, miR-138-5p is sponged by circ_0075804 and forms a ceRNA axis with one of the targets of miR-138-5p, PEG10, which increases its expression and leads to a malignant phenotype (36). Bcl-2-family proteins play critical roles in cell death regulation, regulating various cell death mechanisms such as apoptosis, necrosis, and autophagy (164, 165). Increased viability, metastasis, and invasion in RB occur...
due to increased expression levels of BCL-2 in the form of the ceRNA axis circ_0000527/miR-646/BCL-2 (26). SLC7A5 imports essential amino acids into cancer cells, and research has shown that amino acids, particularly leucine, activate mTORC1, which regulates protein translation and cell growth, and inhibits apoptosis in malignant cells by activating mTORC1 (166, 167). Circ-FAM158A and SLC7A5 are overexpressed in RB. SLC7A5 acts as a lever to demonstrate the oncogenic properties of circ-FAM158A (39).

As mentioned, the genes considered so far in the studies, including genes with potential and influence in the processes involved in cancer, play an essential role in the development of RB. The localization of these essential genes in the ceRNA axes indicates the potential of these axes in cancer causation and emphasizes the principle that molecular mechanisms, especially ceRNA axes, should be further studied.

5 LIMITATIONS

The present study had several limitations. On the one hand, ceRNA studies centered on circRNAs are just beginning, and the number of such studies is limited. This study tried to be a roadmap for further studies in this field and increase attention and enthusiasm for future studies in RB. On the other hand, we attempted to cover all of the details pertaining to these regulatory axes and circRNAs in Table 1 in the section on key findings. All care was taken not to miss a study during the screening process, and three persons collaborated on this part so that this study would include all of the studies conducted in the field of RB, but this is conceivable due to an individual error that may have left a study off the table.

6 CONCLUSION

Numerous circRNAs have been discovered and studied in recent years. CircRNAs act as miRNA sponges, influencing the expression of related genes and forming a regulatory axis called ceRNA. CeRNA axes are potential axes that function from disease onset to diagnosis and treatment. This study gathered evidence that circRNAs had a fascinating impact on essential genes in RB, each of which has the potency to be a defining characteristic of this cancer. Thus, our efforts to understand different aspects of ceRNA regulation processes in RB pathogenesis provide new insights into potential molecular targets, identify ceRNA-based diagnostics, and develop ceRNA-based therapeutic potential.

AUTHOR CONTRIBUTIONS

MT and MA wrote the draft and revised it. MR and AR designed and supervised the study. BH, HS, MM, MS-B and PH collected the data and designed the figures and tables. All the authors read and approved the submitted version.

ACKNOWLEDGMENTS

We would like to thank the Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences, Tabriz, Iran for their assistance in this research.

REFERENCES

1. Knudson AG Jr. Mutation and Cancer: Statistical Study of Retinoblastoma. Proc Natl Acad Sci U S A (1971) 68(4):820–3. doi: 10.1073/pnas.68.4.820
2. Abramson DH, Scheffer AC, Beaverson KL, Rollins IS, Ruddat MS, Kelly CJ. Rapid Growth of Retinoblastoma in a Premature Twin. Arch Ophthalmol (2002) 120(9):1232–3. doi: 10.1001/archopht.120.9.1232
3. Fabian ID, Onadim Z, Karaa E, Duncan C, Chowdhury T, Scheimberg I, et al. The Management of Retinoblastoma. Oncogene (2018) 37(12):1551–60. doi: 10.1038/s41388-017-0050-x
4. Kiss S, Leiderman YI, Mukai S. Diagnosis, Classification, and Treatment of Retinoblastoma. Int Ophthalmol Clin (2008) 48(2):135–47. doi: 10.1097/IO.0b013e3181693670
5. Shields CL, Shields JA, De Potter P, Minelli S, Hernandez C, Brady LW, et al. Plaque Radiotherapy in the Management of Retinoblastoma. Use as a Primary and Secondary Treatment. Ophthalmology (1993) 100(2):216–24. doi: 10.1016/S0161-6420(93)31666-7
6. Murphree AL, Villalba JG, Deegan WF3, Sato JK, Malogolowkin M, Fisher A, et al. Chemotherapy Plus Local Treatment in the Management of Intraocular Retinoblastoma. Arch Ophthalmol (1996) 114(11):1348–56. doi: 10.1001/archoph.1996.01100140548005
7. Yanić Ö, Güçüdz K, Yavuz K, Tacyıldız N, Ünal E. Chemotherapy in Retinoblastoma: Current Approaches. Turk J Ophthalmol (2015) 45(6):259–67. doi: 10.4274/tjop.068888
8. Sabaie H, Amirinejad N, Asadi MR, Jalai A, Daneshmandpour Y, Rezaei O, et al. Molecular Insight Into the Therapeutic Potential of Long Non-Coding RNA-Associated Competing Endogenous RNA Axes in Alzheimer’s Disease: A Systematic Scoping Review. Front Aging Neurosci (2021) 13:742242. doi: 10.3389/fnagi.2021.742242
9. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne) (2018) 9:402. doi: 10.3389/fendo.2018.00402
10. Singh G, Storey KB. MicroRNA Cues From Nature: A Roadmap to Decipher and Combat Challenges in Human Health and Disease? Cells (2021) 10(12). doi: 10.3390/cells10123374
11. Franco-Zorrilla JM, Valli A, Todesco M, Mateos I, Puga MI, Rubio-Somoza I, et al. Target Mimicry Provides a New Mechanism for Regulation of microRNA Activity. Nat Genet (2007) 39(8):1033–7. doi: 10.1038/ng2079
12. Ebert MS, Neilson JR, Sharp PA. MicroRNA Sponges: Competitive Inhibitors of Small RNAs in Mammalian Cells. Nat Methods (2007) 4(9):721–6. doi: 10.1038/nmeth1079
13. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolﬁ PP. A Coding-Independent Function of Gene and Pseudogene mRNAs Regulates Tumour Biology. Nature (2010) 465(7301):1033–8. doi: 10.1038/ nature09144
14. Selbach M, Schwanhäusser B, Thierfelder N, Pﬁger D, Rügheimer M, Rajewsky N. Widespread Changes in Protein Synthesis Induced by microRNAs. Nature (2008) 455(7209):58–63. doi: 10.1038/nature07228
15. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? Cell (2011) 146(3):353–8. doi: 10.1016/j.cell.2011.07.014

16. Kim HH, Kwon Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. HuR Recruits Let-7/RISC to Repress C-Myc Expression. Genes Dev (2009) 23(15):1743–8. doi: 10.1101/gad.1812509

17. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by microRNA-7. J Biol Chem (2009) 284(9):5731–41. doi: 10.1074/jbc.M004280200

18. Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 Circular RNA Retards Cell Cycle Progression via Forming Ternary Complexes With P21 and CDK2. Nucleic Acids Res (2016) 44(6):2846–58. doi: 10.1093/nar/gkw027

19. Sinha T, Panigrahi C, Das D, Chandra Panda A. Circular RNA Translation, a Path to Hidden Proteome. Wiley Interdiscip Rev RNA (2022) 13(1):e1685. doi: 10.1002/wrna.1685

20. Verduci L, Tarcitano E, Strano S, Yarden Y, Blandino G. CircRNAs: Role in Progression of Retinoblastoma by Regulating miR-646/LRP6 Axis. Neurochem Res (2020) 45(7):468. doi: 10.1007/s11010-020-03886-5

21. Levac D, Colquhoun H, O’Brien KJ. Scoping Studies: Towards a Methodological Framework for Cancer Biomarker Discovery. Curr Eye Res (2020) 21(2):441–57. doi: 10.1016/bib/bbz006

22. Arksey H, O’Malley L. Scoping Studies: A Methodological Approach to Exploring Outcomes Research Networks for Cancer Biomarker Discovery. Int J Soc Res Methodol (2015) 18(3):351–361. doi: 10.1080/13645570.2015.1058616

23. Levac D, Colquhoun H, O’Brien KJ. Scoping Studies: Advancing the Methodology. Implement Sci (2010) 5:69. doi: 10.1186/1748-5908-5-69

24. Tricco AC, Lillie E, Zarim W, O’Brien KJ, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med (2018) 169(7):467–73. doi: 10.7326/M18-0850

25. Du S, Wang S, Zhang F, Lv Y. SKP2, Positively Regulated by Circ_ODC1/miR-422a Axis, Promotes the Proliferation of Retinoblastoma. Cell Death Dis (2020) 11(1):322–31. doi: 10.1038/s41419-020-03743-3

26. Chen NN, Chao DL, Li XG. Circular RNA has_Circ_0000527 Participates in Suppressing the Development of Retinoblastoma by Modulating the miR-27a-3p/HDAC9 Pathway. Curr Eye Res (2022) 47(1):115–26. doi: 10.1080/02713683.2021.1925697

27. Zhang XO, Wang RB, Zhang Y, Lu X, Chen LL, Yang L, et al. Complementary Features of Circular RNA Expression. PLoS Genet (2013) 9(3):e1003377. doi: 10.1371/journal.pgen.1003377

28. Zhang XO, Dong R, Zhang Y, Zhang JL, Luo Z, Zhang J, et al. Diverse Multiple miRNAs. Cell Death Dis (2021) 12(7):978. doi: 10.1038/s41419-021-03886-5

29. Wang H, Li M, Cui H, Song X, Sha Q. CircDHDDS/miR-361-3p/WNT3A Pathway Induces PEG10 Expression. Exp Eye Res (2021) 211:108650. doi: 10.1016/j.exer.2021.108650

30. Zuo X, Fu C, Xie J, Wang X, Yan Z. Hsa_circ_0000527 Downregulation Suppresses the Development of Retinoblastoma by Modulating the miR-23a-3p/SMAD2 Pathway. Curr Eye Res (2022) 47(1):115–26. doi: 10.1080/02713683.2021.1925697

31. Suzuki Y, Dou X, Kong Q, Li Y, Zhou X. Circ_0075804 Promotes the Progression of Human Retinoblastoma by Modulating the miR-425-5p/SLC7A5 Axis. Cancers (Basel) (2020) 12(3). doi: 10.3390/cancers12030697
Asadi et al. CircRNA and Retinoblastoma

56. Aktas T, Avşar İlik I, Maticzká D, Bhardwaj V, Pessoa Rodrigues C, Mittler G, et al. DHX9 Suppresses RNA Processing Defects Originating From the Alu Invasion of the Human Genome. *Nature* (2017) 544(7648):115–9. doi: 10.1038/nature21715

57. Yu CY, Li TC, Wu YY, Yeh CH, Chiang W, Chuang CY, et al. The Circular RNA Circhrnc Participates in the Molecular Circuitry Controlling Human Pluripotency. *Nat Commun* (2017) 8(1):1149. doi: 10.1038/s41467-017-01216-w

58. Ebbesen KK, Hansen TB, Kjems J. Insights Into Circular RNA Biology. *RNA Biol* (2017) 14(8):1035–45. doi: 10.1080/15476286.2016.1271524

59. Zhao X, Cai Y, Xu J. Circular RNAs: Biogenesis, Mechanism, and Function in Human Cancers. *Int J Mol Sci* (2019) 20(16). doi: 10.3390/ijms20163926

60. Qu S, Zhong Y, Shang R, Zhang X, Song W, Kjems J, et al. The Emerging Landscape of Circular RNA in Life Processes. *RNA Biol* (2017) 14(8):992–9. doi: 10.1080/15476286.2017.1220473

61. Hansen TB, Jensen TI, Clausen BH, Bransen JB, Finsen B, Damgaard CK, et al. Natural RNA Circles Function as Efficient microRNA Sponges. *Nature* (2013) 495(7441):384–8. doi: 10.1038/nature11993

62. Guo JU, Agarwal V, Guo H, Bartel DP. Expanded Identification and Characterization of Mammalian Circular RNAs. *Genome Biol* (2014) 15(7):409. doi: 10.1186/s13059-014-0409-z

63. Kristensen LS, Hansen TB, Venø MT, Kjems J. Circular RNAs in Cancer: Opportunities and Challenges in the Field. *Oncomge* (2018) 37(5):555–63. doi: 10.1007/s12934-017-0444-1

64. Chen J, Li Y, Zheng Q, Bao C, He J, Chen B, et al. Circular RNA Profile Identifies Circtv1 as a Proliferative Factor and Prognostic Marker in Gastric Cancer. *Cancer Lett* (2017) 388:208–19. doi: 10.1016/j.canlet.2016.12.006

65. Wang PL, Bao Y, Yee MC, Barrett SP, Hogan GJ, Olsen MN, et al. Circular RNA is Expressed Across the Eukaryotic Tree of Life. *PLoS One* (2014) 9(6):e90859. doi: 10.1371/journal.pone.0090859

66. Wang Y, Liu J, Huang BO, Xu YM, Li J, Huang LF, et al. Mechanism of Alternative Splicing and its Regulation. *BioMed Rep* (2015) 3(2):152–8. doi: 10.3922/br.2014.407

67. Li X, Zhang B, Li F, Yu K, Bai Y. The Mechanism and Detection of Alternative Splicing Events in Circular RNAs. *Peerj* (2020) 8:e10032. doi: 10.7717/peerj.10032

68. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-Intron Circular RNAs Regulate Transcription in the Nucleus. *Nat Struct Mol Biol* (2015) 22(3):256–64. doi: 10.1038/nsmb.2959

69. Abdelmohsen K, Panda AC, Munk R, Grammatikakis I, Dudekula DB, De S, et al. Identification of HuR Target Circular RNAs Uncovers Suppression of PABPN1 Translation by Circpabpn1. *RNA Biol* (2017) 14(3):361. doi: 10.1080/15476286.2017.1279788

70. Zhang Y, Zhang X, Cao Y, Chen X, Yang Y, Wang N, et al. Circular Intron: Long Noncoding RNAs. *Mol Cell* (2013) 51(6):792–806. doi: 10.1016/j.molcel.2013.07.018

71. Fischer JW, Leung AK. Circular RNAs: A Regulator of Cellular Stress. *Crit Rev Biochem Mol Biol* (2017) 52(2):220–33. doi: 10.1080/10409238.2016.1267882

72. Du WW, Yang W, Chen Y, Wu ZK, Foster FS, Yang Z, et al. Foxo3 Circular RNA Promotes Cardiac Senescence by Modulating Multiple Factors Associated With Stress and Senescence Responses. *Eur Heart J* (2017) 38(18):1402–12.

73. Li X, Yang L, Chen LL. The Biogenesis, Functions, and Challenges of Circular RNAs. *Mol Cell* (2018) 71(3):428–42. doi: 10.1016/j.molcel.2018.06.034

74. Perriman R, Ares M Jr. Circular mRNA can Direct Translation of Extremely Long Repeating-Sequence Proteins *In Vivo. RNA* (1998) 4(9):1047–54. doi: 10.1071/S13558389980901X

75. Legnini I, Di Timoteo G, Rossi F, Morlando M, Braginti F, Sibrau D, et al. Circ-ZNF609 Is a Circular RNA That Can Be Translated and Functions in Myogenesis. *Mol Cell* (2017) 66(1):32–37.e9. doi: 10.1016/j.molcel.2017.02.017

76. Wang Y, Wang Z. Efficient Backsplicing Produces Translatable Circular mRNAs. *RNA* (2015) 21(2):172–9. doi: 10.1261/rna.048272.114

77. Xin Z, Ma Q, Ren S, Wang G, Li F. The Understanding of Circular RNAs as Special Triggers in Carcinogenesis. *Brief Funct Genomics* (2017) 16(2):80–6.
98. Huang W, Fang K, Chen TQ, Zeng ZC, Sun YM, Huan C, et al. circRNA Circa4f Functions as an Oncogene to Regulate MLL-AF4 Fusion Protein Expression and Inhibit MLL Leukemia Progression. *J Hematol Oncol* (2019) 12(1):103. doi: 10.1186/s13045-019-0880-z

99. Wang X, Jin P, Zhang Y, Wang K. CircSIP1 Acts as an Oncogene in Acute Myeloid Leukemia Through Antagonizing SIP1 and Interacting With microRNAs. *Cell Death Dis* (2021) 12(4):297. doi: 10.1038/s41419-021-03566-2

100. Shi Y, Han T, Liu C. CircRNA Hsa_Circ_00066220 Acts as a Tumor Suppressor Gene by Regulating miR-197-5p/CDH19 in Triple-Negative Breast Cancer. *Ann Transl Med* (2021) 9(15):1236–9. doi: 10.21037/atm-21-2934

101. Wang S, Liu F, Ma H, Cui X, Yang S, Qin R. circCDYL Acts as a Tumor Suppressor in Triple Negative Breast Cancer by Sponging miR-190a-3p and Upregulating Tp53inp1. *Clin Breast Cancer* (2020) 20(5):422–30. doi: 10.1016/j.cbjc.2020.04.006

102. Li XN, Wang ZJ, Ye CX, Zhao BC, Li ZL, Yang Y. RNA Sequencing Reveals the Expression Pro

103. Yan D, Liu W, Liu Y, Zhu X. Circular RNA Circ_0065378 Upregulates the Expression of Circulating Circulatory in Lung Cancer. *Sci Rep* (2015) 5:8057. doi: 10.1038/srep08057

104. Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, et al. Correlation of Circular RNA Abundance With Proliferation–Exemplified With Colorectal and Ovarian Cancer, Idiopathic Lung Fibrosis, and Normal Human Tissues. *Sci Rep* (2015) 5:8057. doi: 10.1038/srep08057

105. Miao X, Xi Z, Zhang Y, Li Z, Huang L, Xin T, et al. Circ-SMARCA5 Suppresses Lung Cancer Proliferation by Competitively Binding With miR-4701-3p and Regulating PRDX2 Protein Expression. *Mol Cancer* (2021) 20(12):335. doi: 10.1186/s12943-021-01203-8

106. Li RC, Ke S, Meng FK, Lu J, Zou XJ, He ZG, et al. Circs-R7 Promotes Growth and Metastasis of Esophageal Squamous Cell Carcinoma via Regulation of miR-7/FoxH13. *Cell Death Dis* (2018) 9(8):838. doi: 10.1038/s41419-018-0852-y

107. Zhang Y, Jiang J, Zhang J, Shen H, Wang M, Guo Z, et al. CircDIDO1 Inhibits Gastric Cancer Progression via miR-374a-3p/KLF14 Axis. *J Exp Clin Cancer Res* (2020) 39(1):160. doi: 10.1186/s13046-020-01642-7

108. Sun W, Zhang H, Duan W, Zhu H, Gu C. Tumor Suppressor Role of the Tumor Suppressor PDCD4: Expression and Functions. *Cell Death Dis* (2018) 9(2):175. doi: 10.1038/s41419-017-0204-3

109. Zheng J, Liu X, Xue Y, Gong W, Ma J, Xi Z, et al. TTBK2 Circular RNA Promotes Glioma Malignancy by Regulating miR-217/ Hnf1β/ Derlin-1 Pathway. *J Hematol Oncol* (2017) 10(1):1–19.

110. Rajappa A, Banerjee S, Sharma V, Khandelia P. Circular RNAs: Emerging Role in Cancer Diagnostics and Therapeutics. *Front Mol Biosci* (2020) 7. doi: 10.3389/fmolb.2020.577938

111. Xing L, Zhang L, Feng Y, Cui Z, Ding L. Downregulation of Circular RNA Hsa_Circ_0001649 Indicates Poor Prognosis for Retinoblastoma and Regulates Cell Proliferation and Apoptosis via AKT/mTOR Signaling Pathway. *BioMed Pharmacother* (2018) 105:326–33. doi: 10.1016/j.biopha.2018.05.141

112. Pan Y, Chen Y, Ma D, Li Z, Cao F, Chen Z, et al. miR-646 Is a Key Negative Regulator of EGFR Pathway in Lung Cancer. *Exp Lung Res* (2016) 42(6):286–95. doi: 10.1080/01906214.2016.1200776

113. Dai H, Hou K, Cai Z, Zhou Q, Zhu S. Low-Level miR-646 in Colorectal Cancer Inhibits Cell Proliferation and Migration by Targeting NOB1 Expression. *Oncol Lett* (2017) 14(6):6708–14. doi: 10.3892/ol.2017.7032

114. Li W, Liu M, Feng Y, Xu YF, Huang YF, Che JP, et al. Downregulated miR-646 in Clear Cell Renal Carcinoma Correlated With Tumor Metastasis by Targeting the Nin One Binding Protein (NOB1). *Br J Cancer* (2014) 111(6):1188–200. doi: 10.1038/bjc.2014.382

115. Wang J, Shu H, Guo S. MiR-646 Suppresses Proliferation and Metastasis of Non-Small Cell Lung Cancer by Repressing FGFR2 and CCND2. *Cancer Med* (2020) 9(12):4360–70. doi: 10.1002/cam4.3062

116. de Ridder I, Kerkhofs M, Veettil SP, Dehaen W, Bultynck G. Cancer Cell Death Strategies by Targeting Bcl-2’s BH4 Domain. *Biochim Biophys Acta Mol Cell Res* (2021) 1868(5):118983. doi: 10.1016/j.bbamcr.2021.118983

117. Matsuhashi S, Manirujjaman M, Hamajima H, Ozaki I. Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Implications in Cancer. *Clin J Cancer* (2015) 34(12):554–62. doi: 10.1186/1333-8906-40-554

118. de Ridder I, Kerkhofs M, Veettil SP, Dehaen W, Bultynck G. Cancer Cell Death Strategies by Targeting Bcl-2’s BH4 Domain. *Biochim Biophys Acta Mol Cell Res* (2021) 1868(5):118983. doi: 10.1016/j.bbamcr.2021.118983

119. Matsumoto S, Manirujjaman M, Hamajima H, Ozaki I. Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions. *Int J Mol Sci* (2019) 20(9). doi: 10.3390/ijms20092304

120. He S, Lu Y, Liu X, Huang X, Keller ET, Qian CN, et al. Wnt3a Functions and Implications in Cancer. *Clin J Cancer* (2015) 34(12):554–62. doi: 10.1186/1333-8906-40-554

121. Yang J, Wahdan-Alaswad R, Danielpour D. Critical Role of Smad2 in Tumor Suppression and Transforming Growth Factor-Beta-Induced Apoptosis of Prostate Epithelial Cells. *Oncogene* (2009) 28(11):2185–90. doi: 10.1186/1332-4012-40-1189

122. Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G, et al. Smad2 and Smad3 Have Opposing Roles in Breast Cancer Bone Metastasis by Differentially Affecting Tumor Angiogenesis. *Oncogene* (2010) 29(9):1351–61. doi: 10.1038/onc.2009.426

123. Jeong W, Jho EH. Regulation of the Low-Density Lipoprotein Receptor-Related Protein LRPs and Its Association With Disease: Wnt/B-Catenin
Signaling and Beyond. Front Cell Dev Biol (2021) 9:714330. doi: 10.3389/fcell.2021.714330

136. Kamura T, Harra T, Kotoshiba S, Yada M, Ishida N, Imaki H, et al. Degradation of p53kip2 Mediated by SCSKip2-Dependent Ubiquitylation. Proc Natl Acad Sci U S A (2003) 100(18):10231–6. doi: 10.1073/pnas.1831099100

137. Bhattacharyya S, Garriga J, Calbo J, Yong T, Haines DS, Graha X. SKP2 Associates With P130 and Accelerates P130 Ubitquitylation and Degradation in Human Cells. Oncogene (2003) 22(16):2443–51. doi: 10.1038/sj.onc.1206339

138. Yu ZK, Gervais JL, Zhang H. Human CUL-1 Associates With the SKP1/SKP2 Complex and Regulates P21CIP1/2/WAF1 and Cyclin D Proteins. Proc Natl Acad Sci U S A (1998) 95(19):11132–8. doi: 10.1073/pnas.95.19.111324

139. Hiramatsu Y, Kitagawa K, Suzuki T, Uchida C, Hattori T, Kikuchi H, et al. Degradation of Tobb Mediated by SCSKip2-Dependent Ubiquitination. Cancer Res (2006) 66(17):8477–83. doi: 10.1158/0008-5472.CAN-06-1603

140. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, et al. Deregulated Expression of HDAC9 in B Cells Promotes Development of Lymphoproliferative Disease and Lymphoma in Mice. Dis Model Mech (2016) 9(12):1483–95.

141. Rastogi B, Raut SK, Panda NK, Rattan V, Radotra BD, Khullar M. Overexpression of HDAC9 Promotes Oral Squamous Cell Carcinoma Growth, Regulates Cell Cycle Progression, and Inhibits Apoptosis. Mol Cell Biochem (2016) 415(1–2):183–96. doi: 10.1007/s11010-016-2690-5

142. Lapiere M, Linares A, Dalvai M, Duraffourd C, Bonnet S, Boulahrouf A, et al. Histone Deacetylase 9 Regulates Breast Cancer Cell Proliferation and the Response to Histone Deacetylase Inhibitors. Oncotarget (2016) 7(15):19693–708. doi: 10.18632/onctarget.7564

143. Zhang Y, Wu D, Xia F, Xian H, Zou X, Cui H, et al. Downregulation of HDAC9 Inhibits Cell Proliferation and Tumor Formation by Inducing Cell Cycle Arrest in Retinoblastoma. Biochem Biophys Res Commun (2016) 473(2):600–6. doi: 10.1016/j.bbrc.2016.03.129

144. Xiong H, Yang Q, Xiao L, Shen HM, Liou YC. STX17 Dynamically Regulated by Fis1 Induces Mitophagy via Hierarchical Macromautophagic Mechanism. Nat Commun (2019) 10(1):2059.

145. Evans MK, Saurer SJ, Nath S, Robinson TJ, Morse MA, Devi GR. X-Linked Inhibitor of Apoptosis Protein Mediates Tumor Cell Resistance to Antibody-Dependent Cellular Cytotoxicity. Cell Death Dis (2016) 7(11):e2073. doi: 10.1038/cddis.2015.412

146. Bang H, Hy SB, Hwang SH, Park CK. Expression of PEG10 Is Associated With Poor Survival and Tumor Recurrence in Hepatocellular Carcinoma. Cancer Res Treat (2015) 47(4):844–52. doi: 10.4143/crt.2014.124

147. Deng X, Hu Y, Ding Q, Han R, Guo Q, Qin J, et al. PEG10 Plays a Crucial Role in Human Lung Cancer Proliferation, Progression, Prognosis and Metastasis. Oncol Rep (2014) 32(5):2159–67. doi: 10.3892/or.2014.3469

148. Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, et al. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep (2015) 12(6):922–36. doi: 10.1016/j.celrep.2015.07.012

149. Reed J, Bel-2 - Family Proteins and Hematologic Malignancies: History and Future Prospects. Blood (2008) 111:3322–30. doi: 10.1182/blood-2007-09-078162

150. Cory S, Huang DC, Adams JM. The Bel-2 Family: Roles in Cell Survival and Oncogenesis. Oncogene (2003) 22(53):8590–607. doi: 10.1038/sj.onc.1207102

151. Bond P. Regulation of Mtorc1 by Growth Factors, Energy Status, Amino Acids and Mechanical Stimuli at a Glance. J Int Soc Sports Nutr (2016) 13:8. doi: 10.1186/s12970-016-0118-y

152. Bar-Peled L, Sabatini DM. Regulation of Mtorc1 by Amino Acids. Trends Cell Biol (2014) 24(7):400–6. doi: 10.1016/j.tcb.2014.03.003

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Asadi, Moslehiyan, Sabzie, Sharifi-Bonab, Hakimi, Hussain, Taheri, Raklison and Rezaazadeh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.